Results 261 to 270 of about 266,977 (390)

Activating types 1 and 2 angiotensin II receptors modulate the hypertrophic differentiation of chondrocytes

, 2014
一郎 墳本
openalex   +1 more source

Angiotensin II Type-2 Receptor Stimulation Prevents Neural Damage by Transcriptional Activation of Methyl Methanesulfonate Sensitive 2 [PDF]

, 2006
Masaki Mogi, Jian‐Mei Li, Jun Iwanami, Li‐Juan Min, Kana Tsukuda, Masaru Iwai, Masatsugu Horiuchi   +6 more
openalex   +1 more source

Angiotensin II Type 2 Receptor Stimulation: A Novel Option of Therapeutic Interference With the Renin-Angiotensin System in Myocardial Infarction?

Circulation, 2008
E. Kaschina, A. Grzesiak, Jun Li, A. Foryst-Ludwig, M. Timm, F. Rompe, M. Sommerfeld, U. Kemnitz, C. Curato, P. Namsolleck, C. Tschöpe, A. Hallberg, M. Alterman, T. Hucko, I. Paetsch, T. Dietrich, B. Schnackenburg, K. Graf, B. Dahlöf, U. Kintscher, T. Unger, U. Steckelings   +21 more
semanticscholar   +1 more source

A Delphi consensus project to capture experts' opinion on hyperkalaemia management across the cardiorenal spectrum

ESC Heart Failure, Volume 12, Issue 2, Page 1132-1140, April 2025.
Abstract The main purpose of this project was to capture experts' opinion on hyperkalaemia management and form best practice recommendations for cardiorenal patients in Greece. A steering committee of nephrologists and cardiologists developed 37 statements. An online questionnaire completed by 32 experts in cardiorenal management in Greece.
Christina Chrysohoou, Maria Marketou, Maria Aktsiali, Ioannis Griveas   +3 more
wiley   +1 more source

Utilizing venous occlusion plethysmography to assess vascular effects: A study with buloxibutid, an angiotensin II type 2 receptor agonist. [PDF]

Clin Transl Sci
Rein-Hedin E, Sjöberg F, Ganslandt C, Skoog J, Zachrisson H, Bengtsson T, Dalsgaard CJ.   +6 more
europepmc   +1 more source

Small molecule angiotensin II type 2 receptor (AT₂R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats.

Pain medicine (Malden, Mass.), 2013
Maree T. Smith, B. Wyse, S. Edwards
semanticscholar   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

A Nonpeptide Angiotensin II Type 2 Receptor Agonist Prevents Renal Inflammation in Early Diabetes

, 2015
Luis C. Matavelli, Roberto Zatz, Helmy M. Siragy   +2 more
openalex   +1 more source

Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT? [PDF]

, 2001
McMurray, John J.V.
core   +1 more source

The Angiotensin II Type 2 Receptor Causes Constitutive Growth of Cardiomyocytes and Does Not Antagonize Angiotensin II Type 1 Receptor–Mediated Hypertrophy

HYPERTENSION, 2005
A. D'Amore, M. Jane Black, Walter G. Thomas   +2 more
semanticscholar   +1 more source